A large randomized controlled trial to determine if mycophenolate mofetil is superior to IV cyclophosphamide in achieving equivalent reduction in proteinuria as induction therapy in patients with WHO class III, IV, and V lupus nephritis.

Time Required (estimated): 20 minutes
Title: Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
Citation: Journal of the American Society of Nephrology 2009, Volume 20, pp. 1103-12
Date Created: 2009
Revisions: None Indicated
Disclaimers: Aspreva Pharmaceuticals (see page 1111)
Resource Type: Text
Other: Presented at ECU Nephrology Journal Club by Dr. Raeesa Mirza on June 15, 2010
Recommend to a Colleague/Friend

Was this teaching resource valuable? Scroll down and complete our 6-point Transparent Peer Evaluation.

Transparent Peer Review
Your reviews are anonymous

[starratingmulti id=”3″]

To learn more about our 6-point transparent peer review system, click here



You must be logged in to post a comment.




Speak your mind

  • Nephrology On-Demand Plus

    Our full-featured iOS app for the iPhone and iPad. NOD + integrates
    1. kidney education,
    2. training, and
    3. recruitment

    into a streamlined and user-friendly interface.


  • Kidney Konnection

    A newsletter that discusses sophisticated topics in Nephrology for physicians in Internal Medicine.
    Click here to access your complimentary subscription